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ASSOCIATIONS OF VITAMIN D WITH HEPATOBILIARY MALIGNANCY 
AND LIVER TRANSPLANTATION IN PATIENTS WITH PRIMARY 
SCLEROSING CHOLANGITIS 
CONNOR PATRICK MULLIGAN 
ABSTRACT 
Primary Sclerosing Cholangitis (PSC) is a progressive cholestatic liver disease 
with outcomes that include hepatobiliary malignancy and liver transplantation. The 
pathogenesis of PSC is incompletely understood and, as a result, few markers of disease 
progression have been identified. Vitamin D is associated with the development and 
treatment of multiple cancers as well as the progression of inflammatory bowel disease, 
making it a possible candidate as a biomarker associated with PSC outcomes. In this 
study, we retrospectively and prospectively collected complete laboratory results and 
outcome datapoints on 179 patients with PSC to determine the association between total 
25(OH)-vitamin D levels, vitamin D supplementation, and both hepatobiliary malignancy 
and liver transplantation. Through survival analysis, we found that history of vitamin D 
supplementation was significantly associated with increased hepatobiliary malignancy-
free and liver transplantation-free survival (p=0.025 and p=0.042, respectively). These 
results indicate that vitamin D is a promising factor associated with the progression of 
PSC to transplantation and malignancy. Future studies on this registry cohort as it 
increases in size and age may provide more conclusive data on the relationship between 
vitamin D and PSC. 
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Overview and Clinical Presentation 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that is 
heterogeneous and can affect both the intra- and extra-hepatic bile ducts. It is commonly 
associated with inflammatory bowel disease (IBD) and progressive inflammation of the 
bile ducts. Patients with this condition experience increased rates of hepatobiliary and 
colorectal malignancy as well as liver failure and transplantation (Tischendorf et al., 
2007). According to meta-analyses of population-based studies, the prevalence of PSC is 
between 6 and 16 per 100,000 in North America and Europe (Molodecky et al., 2011; 
Boonstra et al., 2013). These analyses also found that incidence rates are between 0.5 and 
1 per 100,000 person-years, with evidence that the incidence of PSC is increasing over 
time. Data on prevalence and incidence of PSC from outside of North America and 
Europe is minimal, preventing accurate estimates in other regions. 
 Most patients diagnosed with PSC initially present with minimal symptoms other 
than abnormal liver function tests. The median age at diagnoses is 41 and 60% are male 
(Molodecky et al., 2011; Lazaridis & LaRusso, 2016). One of the most important early 
indications of PSC is a cholestatic profile, defined as elevated Alkaline Phosphatase 
(ALP) for more than six months (Lindor et al., 2015). Once suspected, PSC is then 
confirmed by endoscopic retrograde cholangiopancreatography (ERCP), magnetic 
resonance cholangiopancreatography (MRCP), or liver biopsy. MRCP has become the 
standard for PSC diagnosis as it is the least invasive. ERCP is also common but is 
significantly more invasive and involves risks such as bacterial infection following the 
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procedure. In contrast to MRCP however, ERCP allows for bile duct stricture biopsy and 
the option for further intervention in more advanced cases. The use of liver biopsy is the 
least common, but can detect small duct PSC (Lindor et al., 2015). Even with significant 
advancements in identification and detection of PSC, the average diagnosis is delayed 8.4 
months according to a study of a regional Canadian health system (Kaplan et al., 2007). 
 PSC has two subtypes, one common overlap syndrome, and is significantly 
associated with another gastrointestinal disease. Large duct PSC is the most common 
subtype, with 90% of cases having this morphology (Lazaridis & LaRusso, 2016). This 
subtype effects the entire biliary tree and can be diagnosed via MRCP or ERCP by visible 
biliary strictures (Kaplan et al., 2007). Small duct PSC, the other subtype, is significantly 
less common and only affects intra-hepatic bile ducts, often requiring liver biopsy for 
diagnoses. While patients with small duct PSC often have better outcomes, they can 
suffer recurrence after liver transplantation (Bjornsson et al., 2008). PSC in conjunction 
with autoimmune hepatitis (AIH), sometimes referred to as autoimmune sclerosing 
cholangitis (ASC), is considered an overlap syndrome and found in 7-10% of PSC cases 
(Kaya et al., 2000; Kaplan et al., 2007). PSC-AIH is more commonly found in children 
diagnosed with PSC and can require a liver biopsy to diagnose (Feldstein et al., 2003). 
While PSC-AIH and AIH share similar characteristics and disease processes, differences 
in patient outcomes may indicate that they are distinct disease entities (Gregorio et al., 
2001). In Gregorio et al.’s 2001 study, IBD and biliary histological changes were also 
found to be more common in ASC than AIH. Patients with PSC/AIH overlap also have 
significantly worse outcomes than those with AIH (Heneghan et al., 2008). PSC is also 
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significantly associated with IBD as 70-80% of those with PSC have IBD and 5% of 
those with IBD develop PSC (Loftus et al., 1997). Ulcerative colitis (UC) is more 
common in those with PSC than Crohn’s Disease, and UC is also more genetically 
similar to PSC than Crohn’s Disease (Ji et al., 2017). Overall, it is unclear if PSC-UC is a 
significant risk factor for colorectal malignancy over UC (Loftus et al., 2005).  
 
Pathogenesis 
 While much progress has been made over the last two decades, the pathogenesis 
of PSC remains incompletely understood. It is thought to be influenced by both 
environmental and genetic factors. The prevailing hypothesis is that patients with a 
genetic susceptibility experience an environmental trigger and subsequently develop the 
disease. 
 Few environmental factors have been strongly associated with PSC. In a survey 
study in Oslo on 240 patients with PSC and matched controls, there were fewer coffee 
drinkers and smokers in the PSC cohort than in controls (Andersen et al., 2013). This 
study also found a negative correlation between the use of hormonal birth control and 
PSC in females. Andersen et al. also found that PSC patients were more likely to be 
exposed to farm animals, but not domesticated animals, during childhood. These findings 
are only associational however and have been difficult to connect with genetic and other 
theories of PSC pathogenesis.  
 There is significant evidence of a genetic basis for PSC. In a 2008 study, 
Bergquist et al. found that PSC was 9 to 39 times more common in first-degree relatives 
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of those with confirmed PSC. Interestingly, they also found that UC was more common 
in first-degree relatives of those with PSC without IBD. A genome-wide analyses of 
those with PSC has found significant genetic associations with HLA, suggesting some 
autoimmune component to its pathogenesis (Karlsen et al., 2010). Genetic associations 
with HLA are often complex to interpret however due to its linkage with a breadth of 
different conditions.  
In another 2013 genome-wide analysis of PSC by Liu et al., 12 non-HLA loci 
were found to have significant associations with PSC. Six of these loci displayed more 
significant association with PSC than IBD, reinforcing that they are similar but distinct 
diseases. Many of the loci are involved in immune functions, leading to further interest in 
autoimmune involvement in PSC. One of these loci is located in an intron of salt 
inducible kinase 2 (SIK2), which influences both IL-10 expression in macrophages and 
nerve growth factor IB (Nur77), an important transcription factor in leukocytes (Liu et 
al., 2013). Additionally, this analysis found that two loci significantly associated with 
PSC are involved in mechanisms related to the function of regulatory T cells. One of 
these loci is located in the intron of histone deacetylase 7 (HDAC7) and another, the most 
significantly associated loci, in the intron of serine/threonine-protein kinase D2 
(PRKD2). During T cell selection in the thymus when T cell receptors are engaged, 
PRKD2 phosphorylates HDAC7. This results in the nuclear exclusion of HDAC7 and the 
loss of its functionality in gene regulation, followed by apoptosis and negative selection 
of immature T cells (Liu et al., 2013). This negative selection is also related to the loss of 
HDAC7-mediated repression of Nur77, a locus associated with PSC. Proper functioning 
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of T cell negative selection is essential for immune tolerance and abnormalities in this 
process can lead to autoimmunity, suggesting a potential role for this pathway in PSC. 
Abnormalities in regulatory T cell and T cell levels in general have also been 
found in patients with PSC. Regulatory T cell levels in peripheral blood were 
significantly decreased in those with PSC (Sebode et al., 2015). Variations in the IL2RA 
gene, which also has a locus associated with PSC, is significantly associated with low 
regulatory T cell levels (Liu et al., 2013). Further reinforcing the role of T cells in PSC 
pathogenesis, Sebode et al. (2013) demonstrated that the suppressive capacity of 
regulatory T cells was decreased in PSC. Regulatory T cells are essential in T cell 
selection and their dysfunction can also lead to autoimmunity.  
PSC patients have higher levels of T helper (Th17) cells under pathogen 
stimulation than controls with primary biliary cirrhosis (PBC) (Katt et al., 2013). These T 
helper cells are stimulated under toll-like receptor (TLR) 5 or 7 by the pathogen Candida 
albicans. which has been associated with disease progression in PSC (Katt et al., 2013). 
Also, in the liver of PSC patients most T cells are CD28-, which produce more interferon 
gamma (IF-γ) and tumor necrosis factor alpha (TNF-α) than CD28+ T cells (Liaskou et 
al., 2014). In turn, TNF-α downregulates CD28 in T cells, further increasing the levels of 
CD28- T cells. These CD28- T cells are known to be markers of inflammation, having 
lost CD28 due to continuous antigenic stimulation and TNF-α exposure at inflammation 
sites. They are considered chronically active and less susceptible to regulatory T cells, 
thereby being important drivers of chronic inflammation (Liaskou et al., 2014). In in vitro 
studies of these CD28- T cells however, administration of 1,25(OH)2D3 prevented this 
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downregulation of CD28 by TNF-α, indicating that vitamin D may have an important 
role in the regulation of autoimmune and inflammatory conditions such as PSC (Liaskou 
et al., 2014).   
While genomic and immunologic studies have demonstrated that T cells play an 
essential role in the pathogenesis of PSC, other pathways have also been theorized to 
explain other characteristics of the disease. A 2011 study by O’Hara et al. demonstrated a 
potential inflammatory mechanism in PSC through microbially-derived 
lipopolysaccharide (LPS) and cholangiocytes, the epithelial cells of the bile duct. LPS is 
transported to the liver via the portal system, where it activates TLRs, causing 
cholangiocytes to produce pro-inflammatory markers such as TNF-α (O’Hara et al., 
2011; Szabo et al., 2006). This also results in persistent N-Ras activation and cellular 
senescence, which can further progress into a senescence-associated secretory phenotype 
(SASP) (Tabibian et al., 2014). In normal cholangiocytes and hepatocytes however, TLR 
ligands often fail to elicit an inflammatory response. This is known as TLR tolerance and 
is a defense mechanism again overstimulation by gut endotoxins (Szabo et al., 2006). 
Cholangiocytes and hepatocytes in individuals with PSC however may not exhibit this 
tolerance and instead display pro-inflammatory SASP characteristics. 
Similarly, the umbrella hypothesis of PSC identifies abnormalities in hepatocyte 
and cholangiocyte biochemistry as a potential pathway for PSC pathogenesis. Another 
locus significantly associated with PSC is found in TGR5, which codes for the G-protein 
coupled bile acid receptor 1 (Beners et al., 2010). These receptors, found on 
cholangiocyte membranes, are involves in cAMP modulation of HCO3 secretion. The 
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HCO3 layer is essential for protection against cholangiocyte membrane permeability to 
bile acids, and any deficiency may result in persistent inflammation due to increased 
intracellular levels of bile acids. 
With the strong link between IBD and PSC, gut dysbiosis has also been pursued 
as a potential mechanism for the pathogenesis of PSC. In a 2016 study of gut microbiota, 
Sabino et al. found that PSC was characterized by decreased diversity (Sabino et al., 
2016). The dysbiosis in PSC was distinct from IBD but may result in increased bacterial 
products and endotoxins. The increased levels of endotoxins may then overstimulate 
hepatic immune cells and cholangiocytes, resulting in persistent inflammation and the 
development of PSC (Sabino et al., 2016). 
 
Progression and Outcomes 
 PSC is a progressive inflammatory condition and while most patients are 
asymptomatic upon diagnosis, 76% experience some type of disease progression within 6 
years (Porayko et al., 1990). While much is still unknown about PSC pathogenesis, a 
commonly accepted pathway for disease progression is that bile duct injury and fibrosis 
lead to duct stricturing, cholestasis, biliary cirrhosis, and eventually liver dysfunction and 
failure. During the progressive phase, some of the most common symptoms include 
fatigue, pruritis, abdominal pain, cholestatic itch, and jaundice. As cholestasis develops, 
it has also been found that fat-soluble vitamin deficiency is common (Dyson et al., 2018). 
Once PSC progresses to end-stage liver disease, ascites, variceal bleeding, and hepatic 
encephalopathy are also common. Progression of PSC has extremely dire consequences, 
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as patients with bile duct stenosis have a transplant-free survival rate of 25% over 20 
years (Rudolph et al., 2009). 
 The average survival from PSC diagnosis to LT or death is 21.3 years, with 
studies in liver transplant center cohorts demonstrating shorter survival at 13.2 years 
(Boonstra et al., 2013). Overall, 40% of those with PSC require LT (Tischendorf et al., 
2007). PSC has increasingly become a common indication for LT in the United States, 
with 6% of LT’s from 1988-2015 having an indication of PSC (Lazaridis & LaRusso, 
2016). The 1-year and 5-year survival post-LT for PSC is 85% and 72%, respectively, but 
nearly 50% also experience at least one episode of acute cellular rejection (ACR) 
(Lazaridis & LaRusso, 2016; Fosby et al., 2012). While ACR is often easily treatable 
with immunosuppressants, Fosby et al. (2012) indicated that ACR soon after LT may be a 
risk factor for PSC recurrence. They found that PSC recurrence occurs in 20% of LT 
graphs and may be due to continued immunological attack against bile ducts and liver 
due to the underlying disease, resulting in the early ACR.  
 In addition to liver failure and transplantation, PSC is a significant risk factor for 
hepatobiliary malignancy, with 10.5% of PSC patients developing hepatocellular 
carcinoma (HCC), cholangiocarcinoma (CCA), or pancreatic cancer in a study with an 
average of 11-years of follow-up (Fevery et al., 2011). Hepatobiliary malignancies are 
often extremely difficult to detect however, especially in PSC which mimics many of its 
features, and studies of autopsy reports in PSC have demonstrated even higher rates 
(Burak et al., 2003). While some biochemical tests, such as bilirubin and ALP, have been 
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associated with hepatobiliary malignancies, these tests may only reflect progression of 
the underlying PSC and early detection remains difficult (Yachimski & Pratt, 2008).  
 Among hepatobiliary cancers, CCA is particularly common in PSC, with an 
annual risk of 2% and 30-year risk of 20% (Rizvi et al., 2015). PSC has become a major 
risk factor for CCA in western countries, contributing to poor outcomes as CCA mortality 
increases (Yachimsky & Pratt, 2008; Patel, 2001). There are no effective medical 
treatments for CCA, or other hepatobiliary malignancies associated with PSC. Due to the 
difficulty in detection, the vast majority present with advanced disease that prevents 
resection or other treatment options (Yachimski & Pratt, 2008). Preemptive LT for 
cholangiocarcinoma has been considered, but most PSC patients do not meet current 
standards for long-term survival necessary for LT consideration (Dyson et al., 2018). 
With few treatment options, the long-term outcome for hepatobiliary cancer in PSC is 
dire. In Fevery et al.’s 2011 study in PSC, there was a 45.9% mortality rate among those 
who developed malignancy. 
 Given the poor outcomes of PSC, finding reliable treatment options is extremely 
important, but due to the incomplete understanding of its pathogenesis, few such options 
exist. One of the most prescribed treatments, Ursodeoxycholic acid (UDCA), improves 
the results of liver function tests such as ALP, but its effects on outcomes is 
controversial. In 2009, Lindor et al. terminated a randomized, double-blind study of high-
dose (28-30mg/kg/day) UDCA due to increased serious adverse events in the treatment 
cohort and found that endpoints such as LT and death were 2.3 times more likely in those 
who received the treatment compared to placebo. In another randomized study of UDCA 
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conducted in 2008 by Cullen et al., a similar dose was found to significantly increase 
survival probability according to the Mayo Risk Score. While these studies demonstrate 
conflicting results, the Cullen et al. study which found that UDCA is safe and effective 
had significantly shorter follow-up and relied upon calculated survival probabilities. As a 
result of these studies and other data, the 2015 American College of Gastroenterology 
Clinical Guidelines for PSC do not recommend high dose UDCA for the treatment of 
PSC (Lindor et al., 2015). Data on the use of medium dose UDCA however is lacking, 
but it remains a frequently used treatment for PSC. 
 
Vitamin D in PSC 
 Few prognostic indicators for PSC progression and outcomes have demonstrated 
both statistical and clinical significance, but Vitamin D has been associated with 
hepatobiliary cancer and liver disease progression. While Vitamin D is primarily 
associated with calcium regulation, it also has been found to have potent anti-cancer and 
immunological effects (Deeb et al., 2007).  
Low vitamin D levels are associated with multiple cancers including breast, 
colon, and prostate (Hargrove et al., 2014). Not only have vitamin D and its analogs 
demonstrated anti-proliferative, pro-apoptotic, and other anti-cancer effects, but they may 
also enhance other chemoprotective mechanisms such as DNA repair, antioxidant 
protection, and immunomodulation (Deeb et al., 2007). Specifically, in the case of 
hepatobiliary cancers, the administration of vitamin D in mice models with liver cancer 
significantly decreased tumor growth (Pourgholami et al., 2000). In an in vitro study of 
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human CCA cells, Chiang et al. (2014) found that vitamin D decreased expression of 
LCN2, a potential oncogene, as well as cell proliferation. Vitamin D was also tested in 
vitamin D receptor (VDR) knockout cell lines and demonstrated similar effects on LCN2, 
confirming its role on modulating expression (Chiang et al., 2014). A similar study by 
Kennedy et al. (2013) also found that vitamin D increased VDR expression in CCA 
tumor cells and reduced growth. As a result of these findings, it has been hypothesized 
that vitamin D may play an important role in hepatobiliary cancer outcomes, but its role 
in the development of these malignancies, especially in PSC, remains incompletely 
understood. Ananthakrishnan et al. (2014) has demonstrated that low plasma vitamin D is 
associated with malignancy, especially colorectal cancer, in patients with IBD, indicating 
that it may also play a role in PSC. 
While the effects of Vitamin D on cancer outcomes have been well characterized, 
little is known about its effect on PSC progression and outcome. A 2011 study by Ulitsky 
et al. found that vitamin D deficiency is associated with lower health-related quality of 
life scores and less disease activity in Crohn’s Disease, prompting much interest in its use 
as a prognostic indicator. Calcitriol, the hormonally active form of vitamin D, inhibits the 
production of pro-inflammatory cytokines and reduces the activation of NF-κB, both of 
which are suggested to be involved in the pathogenesis and progression of PSC (Krishnan 
& Feldman, 2010). VDR, which is expressed by T cells, is also required for the 
development of natural killer T cells as well as other types of intra-hepatic lymphocytes 
(Ooi et al., 2012). Additionally, VDR polymorphisms in PSC have been associated with 
worse questionnaire scores related to itch, fatigue, and cognitive capacity, indicating a 
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link between the polymorphism and PSC-related symptoms (Kempinska-Podhorodecka et 
al., 2017). 
Given the associations with cancer, liver disease, and proposed immunologic 
mechanisms for PSC pathogenesis, further investigation of vitamin D and its relation to 
PSC progression and outcome is needed. The high rates of LT, hepatobiliary cancer, and 
death in PSC indicate a present need for viable treatment options. Improved 
understandings of PSC pathogenesis and progression, however, are essential to the 





 Patients with primary sclerosing cholangitis face high proportions of liver 
transplantation, hepatobiliary malignancy, and death, but few treatment options exist due 
to an incomplete understanding of its pathogenesis. Additionally, few useful biomarkers 
have been found to indicate the severity of PSC progression and chance of transplantation 
or malignancy. In this study, we seek to leverage a PSC registry at Massachusetts General 
Hospital and the Brigham and Women’s Hospital to determine the association of 25(OH)-
vitamin D with outcomes such as liver transplantation and hepatobiliary malignancy. We 
also look at the role of vitamin D supplementation in PSC. Vitamin D may be an 
important predictive marker for PSC, and we seek to better understand its relationship to 
two of the most common and severe outcomes.      
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METHODS 
Cohort Identification and Recruitment 
Patients with a diagnosis of primary sclerosing cholangitis were prospectively 
recruited into a registry at two large academic hospitals in Boston, Massachusetts 
(Massachusetts General Hospital and the Brigham and Women’s Hospital). Since 2010, a 
total of 238 patients over 14 years of age and with primary sclerosing cholangitis 
confirmed by clinically standard endoscopic or histologic measures have been enrolled 
into the registry. Of these, 179 patients had a complete medical history available and 
were included in these analyses. 
Data Collection 
Demographic and other general patient information was collected from the 
registry database, which is updated on a yearly basis from electronic medical records. 
The date of PSC diagnosis, defined as date of first confirmation by endoscopic or 
histologic measures, was collected from current medical records. The date of last follow 
up was collected from medical records as the latest patient visit in the gastroenterology or 
transplant departments. Endpoints such as history of hepatobiliary malignancy and liver 
transplantation were also updated from current electronic medical records. The three most 
recent total vitamin D (25(OH)-vitamin D, Total) levels and history of supplementation 
were abstracted, if available, from current electronic medical records. If any of the three 
most recent vitamin D laboratory tests were completed after an endpoint was reached, 
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this information was discarded and replaced with vitamin D levels obtained prior to the 
endpoint(s). 
 
Covariates and Endpoints 
 The covariates of interest for this study are total vitamin D level and history 
of vitamin D supplementation. Data was also collected on patient age, body mass index 
(BMI), sex, race, ethnicity, type of PSC, type of IBD, history of Ursodeoxycholic acid 
(UDCA) treatment, smoking status, and form of vitamin D supplementation. The primary 
outcome and endpoint of interest is hepatobiliary malignancy, which includes 
cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. Liver transplant 
was also an endpoint of interest. 
 
Statistical Analysis 
 Categorical variables are listed as both raw count and percentages. Continuous 
variables are presented as median (interquartile range) or mean ± standard deviation 
based on their normality. Categorical data were compared using chi-square or the Fisher 
exact test as appropriate. Continuous data were compared using the Mann-Whitney U 
test. Survival analysis was completed using Kaplan Meier curves. The Cox Proportional 
Hazards Model using the score (log-rank) test of statistical significance was used to 
perform univariate and multivariate regression analysis with both endpoints of interest. 
Statistical significance was identified at a p-value less than 0.05. Statistical analysis was 





General Vitamin D Characteristics 
 A total of 179 patients diagnosed with primary sclerosing cholangitis had 
complete medical history and vitamin D data and were included in these analyses out of a 
total of 238 patients in the registry. Of these, 59 (37%) had a history of vitamin D 
supplementation while 120 (67%) had no history of vitamin D supplementation prior to 
the most recent vitamin D laboratory test or endpoint (Table 1). Cholecalciferol (1000 
units/day) was the most common form of vitamin D supplementation (n=51, 87%), with 
ergocalciferol (50000 units/week, n=6, 10%) and calcium-citrate-D3 (600 units/day, n=2, 
3%) following. The average most recent vitamin D level was 34.8 ±1.16 ng/ml. Total 
vitamin D levels were also stratified by standard ranges (20-50 ng/ml), with 29 (16%) 
patients being considered vitamin D deficient and 150 (84%) being within the normal 
range.  
 
Table 1. General Characteristics of Vitamin D Levels and Supplementation 
Vitamin D Supplementation  
 Yes 59 (33%) 
 No 120 (67%) 
Type of Vitamin D Supplementation  
 Cholecalciferol 51 (87%) 
 Ergocalciferol 6 (10%) 
 Ca-Cit-D3 2 (3%) 
Latest Vitamin D Level  
 Average (ng/ml) 34.8  ±1.16 
 Normal 150 (84%) 






 In total out of 179 patients, 13 (8%) experienced hepatobiliary malignancy, with 
cholangiocarcinoma (n=9, 5%) being the most common (Table 2). Liver transplant was 
more common however (n=23, 13%). 
 
Table 2. Summary Characteristics of Measured Outcomes 
Hepatobiliary Malignancy  
 Cholangiocarcinoma 9 (5%) 
 Hepatocellular Cancer 3 (2%) 
 Pancreatic Cancer 1 (1%) 
 None 166 (93%) 
Liver Transplant 23 (13%) 
 
 
Demographic and Other Characteristics 
 Cohort demographic information was stratified by history of vitamin D 
supplementation as shown in Table 3. The two cohorts were significantly different in 
terms of racial and ethnic proportions (p=.002 and p=.01, respectively), with a larger 
percentage of the non-supplement cohort having an unknown ethnicity (n=22, 18%) and 
being of a white racial background (n=114, 94%). History of vitamin D supplementation 
was also significantly associated with the most recent total vitamin D level (37 vs. 32 
ng/ml, p=.02). While not statistically significant, vitamin D supplementation tended to be 






Table 3. Association of Vitamin D Supplementation with Cohort Characteristics 
 Vitamin D 
Supplementation 
(n=59) 






Age 48.0 ±24.25 45.0 ±29.3 .32 
BMI 25.3 ±6.0 25.1 ±5.6 .25 
Sex   .56 
 Male 37 (63%) 82 (68%)  
 Female 22 (37%) 38 (32%)  
Race   .002 
 White 46 (78%) 114 (95%)  
 Black 3 (5%) 3 (3%)  
 Asian 5 (9%) 2 (2%)  
Ethnicity   .01 
 Hispanic 4 (7%) 2 (2%)  
 Unknown 3 (5%) 22 (18%)  
PSC Diagnosis   .87 
 Large Duct 46 (78%) 90 (75%)  
 Small Duct 8 (14%) 17 (14%)  
 PSC/AIH 5 (9%) 13 (11%)  
Type of IBD   .52 
 Crohn’s 12 (20%) 17 (14%)  
 UC 35 (59%) 69 (58%)  
 None 12 (20%) 28 (23%)  
UDCA Treatment   .10 
 Current 45 (76%) 78 (65%)  
 Past 10 (17%) 17 (14%)  
 Never 4 (7%) 20 (17%)  
Smoking Status   0.12 
 Current 2 (3%) 2 (2%)  
 Former 4 (7%) 16 (13%)  
 Never 53 (90%) 96 (80%)  
Vitamin D Level 37.0 ±14.5 32.0 ±17.2 .02 
Hepatobiliary Malig. 1 (2%) 12 (10%) .06 
Liver Transplant 4 (7%) 19 (16%) .14 
Abbreviations: BMI=Body Mass Index, PSC=Primary Sclerosing Cholangitis, IBD=Inflammatory Bowel Disease, 
UC=Ulcerative Colitis, UDCA=Ursodeoxycholic acid. 
 
 
Standard Association of Total Vitamin D with Endpoints 
 Total vitamin D levels was not significantly associated with hepatobiliary 
malignancies (44.08 vs. 33.97 ng/ml, p=.306) as seen in figure 1. Lower vitamin D levels 
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were similarly not significantly associated with liver transplantations (35.47 vs. 26.72 
ng/ml, p=.26) as seen in figure 2. 
 
Figure 1. The association between vitamin D level and Hepatobiliary 
malignancy (33.97 vs. 44.08 ng/ml, p=0.306). Hepatobiliary malignancy 









Figure 2. The association between vitamin D level and liver 
transplantation (35.47 vs. 26.72 ng/ml, p=0.26). 
 
 
Average Survival Rates 
 The average 1, 5, 10, and 20-year hepatobiliary malignancy-free and liver 
transplantation-free survival rates of patients with PSC are listed in table 4. Over one year 
of follow-up, an average of 1.7% of PSC patients will develop hepatobiliary malignancy 
and 2.2% will undergo liver transplantation according to our model with 3 and 4 events 
over that time period, respectively. Over 20 years of follow-up, an average of 11.9% of 
PSC patients will develop hepatobiliary malignancy and 23.4% will undergo liver 
transplantation with 12 and 22 events over that time period respectively in our cohort. 
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Table 4. Hepatobiliary Malignancy-free and Liver Transplantation-free Survival Rates 
Hepatobiliary Malignancy 
1-year 98.3% ± 0.01 (3 Events) 
5-year 97.1% ± 0.01 (5 Events) 
10-year 91.0% ± 0.03 (11 Events) 
20-year 88.1% ± 0.04 (12 Events) 
Liver Transplantation 
1-year 97.8% ± 1.11 (4 Events) 
5-year 94.6% ± 1.77 (9 Events) 
10-year 86.3% ± 3.12 (18 Events) 
20-year 76.6% ± 5.57 (22 Events) 
Survival Analysis: Hepatobiliary Malignancy 
Over both 15 and 5 years of follow-up, there was not a significant difference in 
hepatobiliary malignancy-free survival between PSC patients with normal and deficient 
(<20 ng/ml) 25(OH)-vitamin levels (p=0.87 and p=0.89, respectively; Figures 3 & 4). 
When grouped by history of supplementation, there was a significant difference in 
hepatobiliary malignancy-free survival in PSC patients over both 15 and 5 years of 
follow-up (p=0.028 and p=0.025, respectively; Figures 5 & 6). 
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Figure 3. Kaplan Meier survival curve of hepatobiliary malignancy-free 
survival between PSC patients with deficient and normal 25(OH)-vitamin 
D levels (p=0.87). Cut-off of 15 years of follow-up. 
Figure 4. Kaplan Meier survival curve of hepatobiliary malignancy-free 
survival between PSC patients with deficient and normal 25(OH)-vitamin 




Figure 5. Kaplan Meier survival curve of hepatobiliary malignancy-free 
survival between PSC patients with or without history of vitamin D 




Figure 6. Kaplan Meier survival curve of hepatobiliary malignancy-free 
survival between PSC patients with or without history of vitamin D 
supplementation (p=0.025). Cut-off of 5 years of follow up. 
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Univariate and Multivariate Analysis: Hepatobiliary Malignancy 
 Upon univariate analysis using the Cox Proportional Hazards Model, both 
25(OH)-vitamin D levels and history of vitamin D supplementation were significantly 
associated with hepatobiliary malignancy (p=0.02 and p=0.03, respectively). No 
covariates were significant in multivariate analysis. History of vitamin D 
supplementation was associated with a decrease in hazard (increased survival) by a factor 
between 0.018 and 1.081. Vitamin D levels were associated with an increased hazard 
(decreased survival) by a factor between 1.005 and 1.065. 
 





  95% CI (HR)   95% CI (HR)  
 Beta Lower Upper P-
Value 
Beta Lower Upper P-
Value 
Age  0.028 0.995 1.063 0.09     
BMI -0.090 0.814 1.027 0.20     
Sex (Male)  0.974 0.586 11.95 0.20     
Ethnicity -6,3e-
01 
0.069 4.111 0.60     
PSC(Small) -1.058 0.045 2.677 0.31     
UDCA -0.430 0.081 5.207 0.69     
Vit. D 0.034 1.005 1.065 0.02     
Suppl. -1.963 0.018 1.081 0.03     
Abbreviations: BMI=Body Mass Index, PSC=Primary Sclerosing Cholangitis, UDCA=Ursodeoxycholic acid, 
CI=Confidence Interval, HR=Hazard Ratio, Suppl.=History of Vitamin D Supplementation 
 
 
Survival Analysis: Liver Transplantation 
 Over both 25 and 5 years of follow-up, there was not a significant difference in 
liver transplantation-free survival between PSC patients with normal and deficient (<20 
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ng/ml) 25(OH)-vitamin levels (p=0.58 and p=0.28, respectively; Figures 7 & 8). When 
grouped by history of supplementation, there was a significant difference in liver 
transplantation-free survival in PSC patients over both 15 and 5 years of follow-up 
(p=0.049 and p=0.042, respectively; Figures 9 & 10). 
 
 
Figure 7. Kaplan Meier survival curve of liver transplantation-free 
survival between PSC patients with deficient and normal 25(OH)-vitamin 





Figure 8. Kaplan Meier survival curve of liver transplantation-free 
survival between PSC patients with deficient and normal 25(OH)-vitamin 
D levels (p=0.28). Cut-off of 5 years of follow-up. 
 
Figure 9. Kaplan Meier survival curve of liver transplantation-free 
survival between PSC patients with or without history of vitamin D 




Figure 10. Kaplan Meier survival curve of liver transplantation-free 
survival between PSC patients with or without history of vitamin D 
supplementation (p=0.042). Cut-off of 5 years of follow up. 
 
 
Univariate and Multivariate Analysis: Liver Transplantation 
 Upon univariate analysis using the Cox Proportional Hazards Model, both BMI 
and history of vitamin D supplementation were significantly associated with liver 
transplantation (p=0.006 and p=0.04, respectively). BMI and history of vitamin D 
supplementation were also significant upon multivariate analysis (p=0.004 and p=0.024). 
History of vitamin D supplementation was associated with a decreased hazard (increased 
survival) by a factor between 0.117 and 1.018. BMI was associated with a decreased 










  95% CI (HR)   95% CI (HR)  
 Beta Lower Upper P-
Value 
Beta Lower Upper P-
Value 
Age  0.012 0.988 1.036 0.3     
BMI -0.114 0.830 0.959 0.006 -1.1e-
01 
0.835 0.966 0.004 
Sex (Male) -0.495 0.267 1.391 0.20     
Ethnicity  0.170 0.159 8.855 0.87     
PSC(Small) -0.794 0.106 1.935 0.29     
IBD (UC) -4.8e-
01 
0.2144 1.776 0.37     
UDCA  9.4e-
02 
0.374 3.232 0.86     
Vit. D -0.020 0.951 1.01 0.19     
Suppl. -1.062 0.117 1.018 0.04 -1.33 0.0833 0.840 0.024 
Abbreviations: BMI=Body Mass Index, PSC=Primary Sclerosing Cholangitis, IBD=Inflammatory Bowel Disease, 
UC=Ulcerative Colitis, UDCA=Ursodeoxycholic acid, CI=Confidence Interval, HR=Hazard Ratio. Suppl.=History of 









 In this study, we investigated the association between 25(OH)-vitamin D and both 
hepatobiliary malignancy and liver transplantation in a registry of 179 patients with PSC 
at two urban academic medical centers in the United States. We also sought to determine 
the effects of vitamin D supplementation on these outcomes. Our survival analyses 
demonstrated that vitamin D supplementation was associated with increased 
hepatobiliary malignancy-free and liver transplantation-free survival over a 5-year 
follow-up period. We also found that vitamin D deficiency, defined as 25(OH)-vitamin D 
< 20ng/ml, was not significantly associated with hepatobiliary malignancy-free or liver 
transplantation-free survival.  
 
25(OH)-vitamin D, Supplementation, and Hepatobiliary Malignancy 
 Over a 20-year follow-up period, we calculated via Kaplan-Meier survival curves 
from our cohort data an expected rate of hepatobiliary malignancy of 11.9% in PSC 
patients. This aligns with the lower end of the hepatobiliary malignancy rate in PSC 
patients of 13-20% found in Fevery et al’s 2012 study. The 88.1% hepatobiliary 
malignancy-free survival rate is even higher than expected however considering that 
Burak et al. (2003) found that hepatobiliary malignancy rates tend to be higher in biopsy 
studies due to the difficulty in detection. While our finding is within the expected range, 
other factors such as differing rates of cancer screening, vitamin supplementation, and 
various clinical factors may have contributed to our calculated survival being higher than 
that found in other studies. Additionally, the survival analysis we employed projects the 
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survival rate to an exact 20-year follow-up period compared to traditional analyses which 
often utilize exact percentages based upon event rates in their study cohort. The relative 
similarity between our findings and that of other benchmark studies demonstrates the 
generalizability of our registry cohort to the wider PSC population. 
 Standard, time-independent statistical analyses did not demonstrate a significant 
association between 25(OH)-vitamin D or history of vitamin D supplementation and 
hepatobiliary malignancy. In contrast, survival analysis via Kaplan-Meier curves 
demonstrated that PSC patients with a history of vitamin D supplementation experience 
increased hepatobiliary malignancy-free survival at a statistically significant rate. The 
difference in these findings is most likely because hepatobiliary malignancy is not 
normally distributed over the follow-up period. In a 2009 study, Claessen et al. found that 
the median interval between PSC and CCA diagnosis was 2.5 years and Dyson et al. 
(2018), in a The Lancet review of PSC, stated that most CCA was identified within one 
year of PSC diagnosis. These results indicate that the majority of hepatobiliary 
malignancies occur early in the follow-up period, making standard, time-independent 
analyses less suitable as they assume a normal distribution of events. Survival analysis 
accounts for this time-dependent skewed distribution of events and demonstrated 
statistically significant differences in hepatobiliary malignancy-free survival between 
patients with and without a history of vitamin D supplementation. 
 Our analysis demonstrated no significant differences in hepatobiliary malignancy-
free survival between PSC patients with deficient (<20ng/ml) and normal 25(OH)-
vitamin D levels. There is little prior data on the association between serum vitamin D 
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levels and the incidence of hepatobiliary cancer specifically, but research on other 
gastrointestinal cancers such as colorectal cancer, however, has demonstrated that 
reduced plasma 25(OH)-vitamin D is significantly associated with increased risk in 
patients with IBD (Ananthakrishnan et al., 2014). With the large degree of overlap 
between PSC and IBD, similarities in the effects of plasma vitamin D might be expected, 
but genetic analysis has also demonstrated that there may be some distinction between 
the two diseases (Liu et al., 2013). There may be different mechanisms related to the 
effects of vitamin D between colorectal cancer in IBD and hepatobiliary cancer in PSC. 
Future research on PSC patients with IBD and the rates of colorectal vs. hepatobiliary 
malignancy in this population may help answer this question. 
Most prior research has instead focused on the effects of vitamin D on liver tumor 
progression and its usage as a potential treatment option in combination therapies. This 
may correlate with our finding that vitamin D supplementation was significantly 
associated with increased hepatobiliary malignancy-free survival. For example, Hammad 
et al. (2013) demonstrated that declining levels of vitamin D was significantly associated 
with progressive HCC. Similarly, Baek et al. (2011) and Pourgholami et al. (2000) found 
that administration of vitamin D reduced the proliferation of CCA and HCC cell lines, 
respectively. Chiang et al. (2014) further demonstrated the chemotherapeutic effects of 
dietary vitamin D supplementation on CCA in an animal model. Our findings on the 
effects of vitamin D supplementation reinforce the translational applicability of these 
findings to humans with PSC. 
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Whether our results demonstrate a predictive effect of vitamin D supplementation 
on hepatobiliary malignancy incidence is particularly difficult to discern because cancers 
such as CCA often present in more advanced stages (Yachimsky & Pratt, 2008). CCA 
and other hepatobiliary malignancies are very difficult to detect in the early stages, as 
there are often few symptomatic stages. As a result, it is unclear whether vitamin D 
supplementation is decreasing hepatobiliary malignancy survival or reducing the 
proliferation and growth of the tumors. 
Despite this uncertainty, the significant association between vitamin D 
supplementation and hepatobiliary malignancy-free survival demonstrates the importance 
of supplementation in those with PSC, who are at higher risk for hepatobiliary 
malignancy. 
  
25(OH)-vitamin D. Supplementation, and Liver Transplantation 
 According to Boonstra et al. (2013), the average time from PSC diagnosis to 
transplantation or death is 21.3 years in the general PSC population and 13.2 years in a 
liver transplant center cohort. Over 10 and 20-year follow-up periods, we calculated via 
Kaplan-Meier survival curves expected rates of liver transplantation in PSC patients of 
13.7% and 23.4%, respectively (86.3% and 76.6% transplantation-free survival, 
respectively). The PSC cohorts at Massachusetts General Hospital and the Brigham and 
Women’s hospital include patients enrolled from both standard clinics and liver 
transplant centers and the PSC registry reflects both populations. Given that Tischendorf 
et al. (2007) calculated a transplantation rate of 39.6% in a single center cohort study, the 
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transplantation rate found in our PSC registry is significantly lower. The Tischendorf et 
al. study, however, was conduced at the largest transplantation center in Germany which 
may have influenced the results. Additionally, advancements in PSC detection and 
management may have led to better outcomes or longer median time-to-event in PSC 
patients. 
 While much remains uncertain regarding the pathogenesis of PSC, genetic and 
immunologic analyses have demonstrated that T cell dysregulation and dysfunction 
contributes to PSC development and progression. In particular, Liaskou et al. (2014) 
demonstrated the increased prevalence of CD28- T cells in those with PSC and their 
usefulness as inflammatory markers. CD28- T cells are thought to be more prevalent in 
PSC partly due to continuous antigenic stimulation at inflammatory sites, and Katt et al. 
(2013) demonstrated that most T helper cells in PSC patients are under stimulation from 
the pathogen Candida albicans. These studies point to pathogenic and/or endotoxin 
overstimulation of T cells resulting in increased inflammation at the liver and bile ducts, 
which may induce the development and progression of PSC. 
 In addition, Liaskou et al. (2014) demonstrated that, in vitro, administration of 
1,25(OH)2D3 prevented the downregulation of CD28 in T cells. While this finding has 
not been replicated in in vivo studies, it represents a potential pathway through which 
vitamin D may influence inflammation in PSC. Not only has vitamin D been shown to 
have this effect on CD28 regulation, but Liaskou et al. (2014) also found that it increases 
the suppressive action of regulatory T cells, which is important in preventing 
autoimmunity and further inflammation. Some of the most significant non-HLA genetic 
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associations with PSC, such as those influencing HDAC7 and SIK2, also influence 
regulatory T cells and provide another similar pathway through which vitamin D may 
influence PSC pathogenesis and progression (Liu et al., 2013).  
 Our finding that vitamin D supplementation is significantly associated with higher 
liver transplantation-free survival provides additional evidence on the role of vitamin D 
in PSC progression. Similarly, to hepatobiliary malignancy however, 25(OH)-vitamin D 
levels were not significantly associated with liver transplantation-free survival nor lower 
rates of liver transplantation upon standard analysis. Progressive inflammation of the bile 
ducts and liver is a primary characteristic of PSC, and cholestasis, another progressive 
symptom of PSC, has been associated with fat-soluble vitamin deficiency (Dyson et al., 
2018). Vitamin D may play a key predictive and therapeutic role in the progressive 
inflammatory pathway in PSC, and future research on vitamin D and direct inflammatory 
markers or mediators could prove interesting and useful. 
 
BMI and Liver Transplantation-free Survival 
 One of the more surprising results of our univariate and multivariate analysis was 
that higher BMI was significantly associated with a reduced hazard for liver 
transplantation. While high obesity (defined as >30 BMI) contributes to higher morbidity 
in liver diseases such as non-alcohol fatty liver disease as well as in many other 
cardiovascular and renal conditions, there is growing evidence of a “obesity paradox” in 
chronic diseases (Lonardo et al., 2015; Curcic et al., 2019). In this paradox, patients with 
obesity tend to suffer lower mortality compared to those of normal weight, particularly in 
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chronic diseases compared to acute illnesses. Curcic et al. (2019) identified a potential 
obesity paradox effect in chronic liver diseases, especially those that involve cirrhosis. 
The mechanisms behind this effect are still unclear and many of the studies on the obesity 
paradox contain confounding factors, but the body of evidence supporting this finding is 
growing. Our finding of increased BMI in PSC being significantly associated with 
reduced hazard for liver transplantation supports this hypothesis, particularly as cirrhosis 
is often an end-stage symptom of PSC leading to liver transplantation.  
 
Racial and Ethnic Differences in Supplementation 
 Our stratification of the PSC registry into two cohorts based on vitamin D 
supplementation yielded significant differences among race and ethnicity. Racial 
disparities in healthcare are vast, but the differences we found do not follow common 
trends (Nelson, 2002). While our stratification indicated that significantly fewer white 
people with PSC had a history of vitamin D supplementation, a study of Medicare 
recipients demonstrated that Black and Hispanic people were 10 to 40 percent less likely 
to use medications than white persons with the same illness (Briesacher et al., 2003). A 
2013 study by Libon et al. demonstrated however that skin pigmentation is negatively 
associated with vitamin D synthesis. It is unclear whether this factor influenced vitamin 
D supplement prescription and adherence, but it may help explain why our findings on 
vitamin D supplementation differ from research on other prescribed medications. 
Additionally, a higher percentage of the non-supplementing cohort had an unknown 




 While we were able to demonstrate a significant association between vitamin D 
supplementation and survival from both outcomes, hepatobiliary malignancy and liver 
transplantation, 25(OH)-vitamin D levels were not significantly associated with any 
outcomes. The role of vitamin D in PSC progression and outcome is promising, but our 
understanding of its mechanisms and effects is not complete. Even given the unclear 
nature of the role of vitamin D in PSC however, the registry cohort we leveraged in this 
study may not currently be an ideal representation of PSC with which to pursue these 
types of analyses.   
 According to Molodecky et al. (2011), the average age at PSC diagnosis is 41. In 
our PSC registry, the current average age of those with complete data is 45.6 years. Given 
an annual risk of 2% for CCA in PSC, the chance of patients in our cohort developing 
CCA or other malignancies over an average of 4.6 years of follow-up is low (Rizvi et al., 
2015). As the cohort ages and additional data is collected, our analyses will become more 
powered and able to determine associations between variables and endpoints.  
 Additionally, out of 238 total patients with PSC in the registry, only 179 had 
complete vitamin D and outcome data available in their medical records. Many patients 
lacking vitamin D data were enrolled into the registry at earlier dates and experienced 
outcomes that were not able to be included in our analyses. Due to the increasing use of 
electronic medical records and the prevalence of frequent fat-soluble vitamin monitoring 
in PSC however, as the registry ages more patients will have complete data sets available. 
  
37 
This will allow our analyses to better detect relationships between PSC outcomes and 






This study demonstrated a significant association between vitamin D 
supplementation and survival from hepatobiliary malignancy and liver transplantation. 
PSC currently has few widely accepted treatment options in addition to few prognostic 
indicators. Vitamin D may play an important role in the pathogenesis and progression of 
PSC, and its supplementation may be an important factor in preventing adverse 
outcomes. Future studies of vitamin D as both a predictor and treatment option are 
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